COVID-19-associated mucormycosis and treatments

Subramaniyan, Vetriselvan; Fuloria, Shivkanya; Darnal, Hari Kumar; Meenakshi, Dhanalekshmi Unnikrishnan; Sekar, Mahendran; Rusli Nordin; Chakravarthi, Srikumar; Sathasivam, Kathiresan V.; Khan, Shah Alam; Wu, Yuan Seng; Kumari, Usha; Sudhakar, Kalvatala; Malviya, Rishabha; Sharma, Vipin Kumar; Fuloria, Neeraj Kumar; (UniKL RCMP)

Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/26307

Title:	COVID-19-associated mucormycosis and treatments
Authors:	Subramaniyan, Vetriselvan Fuloria, Shivkanya Darnal, Hari Kumar Meenakshi, Dhanalekshmi Unnikrishnan Sekar, Mahendran Rusli Nordin Chakravarthi, Srikumar Sathasivam, Kathiresan V. Khan, Shah Alam Wu, Yuan Seng Kumari, Usha Sudhakar, Kalvatala Malviya, Rishabha Sharma, Vipin Kumar Fuloria, Neeraj Kumar (UniKL RCMP)
Keywords:	COVID-19 Immunosuppression Mucormycosis Pathogenesis Treatment
Issue Date:	Sep-2021
Publisher:	Wolters Kluwer Medknow Publications
Citation:	Fuloria, S., Fuloria, N., Subramaniyan, V., Darnal, H., Meenakshi, D., Sekar, M., Rusli Nordin, Chakravarthi, S., Sathasivam, K., Khan, S., Wu, Y., Kumari, U., Sudhakar, K., Malviya, R., & Sharma, V. (2021). COVID-19-associated mucormycosis and treatments. Asian Pacific Journal of Tropical Medicine, 14(9), 401. https://doi.org/10.4103/1995-7645.326253
Abstract:	In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies
URI:	https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=9;spage=401;epage=409;aulast=Subramaniyan;type=0 http://hdl.handle.net/123456789/26307
ISSN:	19957645
Appears in Collections:	Journal Articles

Files in This Item:

File	Description	Size	Format
COVID-19-associated mucormycosis and treatments.pdf		396.58 kB	Adobe PDF	View/Open

Show full item record